Literature DB >> 3817762

The prognostic value of sulphomucin positive intestinal metaplasia in the development of gastric cancer.

N Ectors, M F Dixon.   

Abstract

Gastric biopsy specimens from 230 patients with chronic atrophic gastritis were investigated with the use of mucin stains for the presence and type of intestinal metaplasia. Metaplasia was not shown in 59 cases; 92 of the 171 cases with metaplasia were sulphomucin positive and 79 were negative. The patients were followed-up from 1976 to 1985. Eight patients were registered as having gastric cancer over this period. However, five of them had to be eliminated from the study because on careful review of all the clinical data it was clear that they had gastric cancer at the time of the biopsy. Two of the three remaining patients had sulphomucin negative biopsies. Thus, only one patient out of 90 with chronic atrophic gastritis and sulphomucin positive intestinal metaplasia developed gastric cancer when followed-up for 8-9 years. None of the patients with unequivocal type IIb metaplasia developed gastric cancer. We conclude that sulphomucin positive intestinal metaplasia does not identify a high risk group and its recognition is thus of no value in surveillance for gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3817762     DOI: 10.1111/j.1365-2559.1986.tb02570.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  19 in total

Review 1.  Oxyntic atrophy, metaplasia, and gastric cancer.

Authors:  James R Goldenring; Ki Taek Nam
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

2.  Detection of sulfated glycoproteins in intestinal metaplasia: a comparison of traditional mucin staining with immunohistochemistry for the sulfo-Lewis(a) carbohydrate epitope.

Authors:  K Bodger; F Campbell; J M Rhodes
Journal:  J Clin Pathol       Date:  2003-09       Impact factor: 3.411

3.  Is intestinal metaplasia a risk for gastric carcinoma?

Authors:  P Sossai; R Cielo; R Barbazza
Journal:  Postgrad Med J       Date:  1989-08       Impact factor: 2.401

4.  Premalignant lesions in gastric cancer.

Authors:  Kazuo Yashima; Shuji Sasaki; Masaharu Koda; Koichiro Kawaguchi; Kenichi Harada; Yoshikazu Murawaki
Journal:  Clin J Gastroenterol       Date:  2009-12-16

Review 5.  Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence.

Authors:  Carlos A González; José M Sanz-Anquela; Javier P Gisbert; Pelayo Correa
Journal:  Int J Cancer       Date:  2013-02-05       Impact factor: 7.396

6.  Expression of small intestinal and colonic phenotypes in complete intestinal metaplasia of the human stomach.

Authors:  Harunari Tanaka; Tetsuya Tsukamoto; Tsutomu Mizoshita; Ken-ichi Inada; Naotaka Ogasawara; Xueyuan Cao; Sosuke Kato; Takashi Joh; Masae Tatematsu
Journal:  Virchows Arch       Date:  2005-08-09       Impact factor: 4.064

7.  Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma.

Authors:  Yao Zheng; Lin Wang; Jian-Ping Zhang; Jing-Yan Yang; Zhu-Mei Zhao; Xiao-Ying Zhang
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

8.  Expression and significance of p53 and mdm2 in atypical intestinal metaplasia and gastric carcinoma.

Authors:  Lin Wang; Xiao-Ying Zhang; Ling Xu; Wen-Jun Liu; Juan Zhang; Jian-Ping Zhang
Journal:  Oncol Lett       Date:  2011-04-14       Impact factor: 2.967

9.  Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up.

Authors:  T Rokkas; M I Filipe; G E Sladen
Journal:  Gut       Date:  1991-10       Impact factor: 23.059

10.  Epidemiological trends of pre-malignant gastric lesions: a long-term nationwide study in the Netherlands.

Authors:  A C de Vries; G A Meijer; C W N Looman; M K Casparie; B E Hansen; N C T van Grieken; E J Kuipers
Journal:  Gut       Date:  2007-08-14       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.